Literature DB >> 6305245

Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation.

J C Wade, J D Meyers.   

Abstract

Six marrow transplant recipients receiving acyclovir at various dosages for herpesvirus infections developed neurologic symptoms during treatment. Three were receiving concomitant human alpha interferon, and all six had received previous intrathecal methotrexate. Symptoms developed a median of 8 days (range, 2 to 18 days) after initiation of therapy and consisted of lethargy or agitation in five patients, tremor in five, and disorientation or transient hemiparesthesias in one patient each. The only consistent laboratory finding was an abnormal electroencephalogram. Five patients had an increased myelin basic protein level in cerebrospinal fluid. Improvement or resolution of symptoms occurred a median of 13 days (range, 4 to 15 days) after cessation of acyclovir therapy. Acyclovir used at a wide range of dosages may be associated with reversible neurologic symptoms in patients after marrow transplantation. The contribution of previous prophylaxis for central nervous system leukemia, herpesvirus infections, marrow transplantation, or the concomitant use of interferon is unknown.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305245     DOI: 10.7326/0003-4819-98-6-921

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

Review 1.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Chemotherapy of herpesvirus infections: present successes and future hopes.

Authors:  S Crowe; J Mills
Journal:  Eur J Clin Microbiol       Date:  1985-10       Impact factor: 3.267

Review 4.  Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature.

Authors:  W A Watson; N J Rhodes; I A Echenique; M P Angarone; M H Scheetz
Journal:  J Clin Pharm Ther       Date:  2017-03-29       Impact factor: 2.512

5.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

6.  Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection.

Authors:  T A Tartaglione; A C Collier; K Opheim; F G Gianola; J Benedetti; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 7.  The role of oral acyclovir in the management of genital herpes simplex.

Authors:  S L Sacks
Journal:  CMAJ       Date:  1987-04-01       Impact factor: 8.262

8.  Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.

Authors:  Jan Lycke; Clas Malmeström; Lars Ståhle
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats.

Authors:  Sriram Gunda; Ravinder Earla; Kishore Cholkar; Ashim K Mitra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-19       Impact factor: 2.441

Review 10.  Genital herpes. A guide to pharmacological therapy.

Authors:  A de Ruiter; R N Thin
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.